Neurocrine Biosciences's quarterly market cap
declined
from Jun. 2024 ($13,891 Mil) to Sep. 2024 ($11,660 Mil) but then
increased
from Sep. 2024 ($11,660 Mil) to Dec. 2024 ($13,568 Mil).
Neurocrine Biosciences's annual market cap
increased
from Dec. 2022 ($11,526 Mil) to Dec. 2023 ($13,005 Mil) and
increased
from Dec. 2023 ($13,005 Mil) to Dec. 2024 ($13,568 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Neurocrine Biosciences's Enterprise Value for Today is $10,421 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Neurocrine Biosciences's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Market Cap falls into.
Neurocrine Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Neurocrine Biosciences's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (NAS:NBIX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Neurocrine Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Neurocrine Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBIX has been successfully added to your 